B cell depletion therapies in autoimmune disease: advances and ... - Nature
2020年12月15日 · Examining B cell depletion therapy (BCDT), an approved treatment for B cell malignancies, in autoimmune conditions has provided key insights into basic B cell biology.
B cell depletion therapies in autoimmune disease: advances …
In this Review, we update our understanding of B cell biology, review the results of clinical trials using BCDT in autoimmune indications, discuss hypotheses for the mechanism of action of BCDT and speculate on evolving strategies for targeting B cells beyond depletion.
B-cell depletion in autoimmune diseases - Annals of the Rheumatic Diseases
In autoimmune disease, B cells orchestrate antigen presentation, cytokine production and autoantibody production, the latter via their differentiation into antibody-secreting plasmablasts and plasma cells. This article addresses the current therapeutic strategies to deplete B cells in order to ameliorate or potentially even cure autoimmune disease.
B-cell depletion in autoimmune diseases - PubMed
2024年10月21日 · In autoimmune disease, B cells orchestrate antigen presentation, cytokine production and autoantibody production, the latter via their differentiation into antibody-secreting plasmablasts and plasma cells. This article addresses the current therapeutic strategies to deplete B cells in order to ameliorate or potentially even cure autoimmune disease.
B cell depletion in autoimmune disease - PMC
In this review we focus on the results of attempts to utilize B cell depletion based on the use of a chimeric monoclonal antibody (MAb) specific for human CD20, rituximab, for the treatment of patients with autoimmune diseases. In 1997, rituximab was approved for the treatment of low-grade B cell non-Hodgkin's lymphoma.
B cell depletion therapies in autoimmune disease: advances and ...
Examining B cell depletion therapy (BCDT), an approved treatment for B cell malignancies, in autoimmune conditions has provided key insights into basic B cell biology. In this Review, Gommerman and colleagues discuss BCDT in autoimmune conditions, highlighting diseases in which BCDT has been clinically effective and the potential and pitfalls ...
Frontiers | B cell depletion therapies in autoimmune diseases ...
2023年2月9日 · In this review, we update our understanding of B cell depletion therapies in autoimmune diseases, review the mechanism, efficacy, safety and application of monoclonal antibodies and CAR-based immunotherapies, and discuss the strengths and weaknesses of these treatment options for patients.
Cutting-edge approaches to B-cell depletion in autoimmune diseases
2024年10月9日 · In this review, we discuss the various BCDTs that are being developed in autoimmune diseases, describing the molecule designs, depletion mechanisms, and potential advantages and disadvantages of each approach as they …
A new perspective on therapies involving B-cell depletion in autoimmune …
2024年5月8日 · B-cell depletion therapies (BCDT), focusing on surface markers like CD20 or CD19, have demonstrated efficacy in certain autoimmune diseases by reducing autoantibody production, modulating the immune response, and potentially alleviating disease symptoms.
B Cells in Health and Disease - Mayo Clinic Proceedings
Preliminary results with the CD20-targeted monoclonal antibody rituximab indicate that rituximab can improve symptoms in a number of autoimmune and neurologic disorders (including rheumatoid arthritis, systemic lupus erythematosus, and paraneoplastic neurologic syndromes).